本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
全球嵌入式系統研發領域之軟體領導者IAR宣佈,正式成為Zephyr Project之銀級會員。Zephyr由Linux基金會託管並廣泛應用於嵌入式產業的開源即時作業系統(RTOS),目前已獲得眾多嵌入式領域之重要企業支持。此次合作充分彰顯了IAR對開源社群的深度承諾,將致力為開發人員提供專業級工具與解決方案,同時協助Zephyr RTOS於嵌入式開發領域的持續發展。 開源即時作業系統 (RTOS) Zephyr 所需的佔位空間小,因此尤其適合資源受限的嵌入式裝置和物聯網(Internet of Things)應用。 Zephy 具備的高度安全性、多元性及可擴展性使其非常適於廣泛應用,範圍涵蓋簡單的家庭自動化感測器到複雜的工業控制器等領域。作為開源軟體,該 RTOS 受益於龐大的社群和持續的改良,並且擁有 Zephyr Project(由Linux Foundation主導的合作專案)及 NXP、Analog Devices 和 Nordic Semiconductor 等領先晶片供應商的全面支持。IAR在2024年10月於Embedded World North America 展示了Zephyr RTOS感知外掛程式,並展現了卓越的整合能力和先進的除錯特性。該展示吸引了眾多觀眾和合作夥伴關注,直覺地呈現該外掛程式如何協助開發人員深入洞察應用程式的即時行為,包括任務監控、調度管理及資源使用情況。此重要里程碑標誌著IAR在融入開源生態、創造客戶價值方面的重要進程。 IAR產品長Thomas Andersson表示:「IAR成為Zephyr Project的銀級會員充分體現我們對開源社群的支援,以及與領先半導體廠商攜手為Zephyr開發者提供領導業界之工具的承諾。我們的目標是連接開源創新性與商業級可靠性,賦能開發人員打造高品質的嵌入式解決方案。」 NXP MCU/MPU生態系統開發總監Brendon Slade表示:「NXP® Semiconductors 對於IAR加入成為銀級會員表示歡迎。作為Zephyr Project 的創始成員和白金會員,NXP高度重視在Zephyr生態系統內的協作以強化客戶的開發體驗。IAR的先進開發工具將進一步強化此生態系統,並提供開發人員先進功能以在NXP平台上創造高性能、安全且可擴展的解決方案。」我們對於IAR成為Zephyr Project會員表示歡迎。Linux Foundation可靠嵌入式系統副總裁Kate Stewart表示:「IAR在嵌入式開發及商業工具方面的專業能力將顯著強化我們的生態系統,使開發者能在由Zephyr 所驅動的專案中創造優化的解決方案。IAR的投入將在需要安全認證工具鏈的領域中強化Zephyr RTOS的功能和採用,鞏固其作為嵌入式開發優選方案的領先地位。」 IAR預計在2025年實現對Zephyr RTOS的全面支援。屆時,開發人員將能運用IAR強大的工具鏈,其中包括了標誌性的優化技術、先進的除錯能力,以及與Zephyr的無縫整合。 歡迎蒞臨2025年在德國舉辦的嵌入式展覽會(Embedded World 2025)體驗IAR與Zephyr RTOS的深度融合!IAR將在3月11日至13日於四展區506號展位展示Zephyr RTOS最新支援方案,並舉辦「探索IAR與Zephyr RTOS的整合」主題講座,展示如何借助該整合方案為嵌入式應用提供卓越的性能與可靠性。 瞭解更多Zephyr Project相關資訊請瀏覽www.zephyrproject.org。瞭解更多IAR如何協助嵌入式開發未來請瀏覽www.iar.com。 關於IARIAR處於為嵌入式開發提供全球領先之軟體和服務的最前端,使全球公司能推出形塑未來的安全和突破性產品。自1983年成立以來,IAR的解決方案在確保品質、安全、可靠性和效率方面發揮了重要價值,為包括汽車、工業自動化、物聯網、醫療科技、軍事及公共安全等眾多產業開發了超過一百萬個嵌入式應用。憑藉對來自超過70個半導體合作夥伴之15,000種裝置之支援,IAR致力於促進創新及協助客戶獲致成功。IAR總部位於瑞典烏普薩拉(Uppsala),並於世界各地策略性地設立業務和支援辦公室,為I.A.R. Systems Group AB子公司,並於納斯達克OMX斯德哥爾摩交易所上市,屬中型股指數(ticker symbol: IAR B)。更多資訊請瀏覽www.iar.com 編輯說明 : IAR、IAR Embedded Workbench、Embedded Trust、C-Trust、C-SPY、C-RUN、C-STAT、IAR Visual State、I-jet、I-jet Trace、IAR Academy、IAR及IAR logo為IAR Systems AB所擁有之商標或註冊商標。所有其他產品名稱均為各自持有者所擁有。
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC) and the company's lead program, for the treatment of patients with platinum-resistant ovarian cancer (PROC). "We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial have been encouraging, and this designation will expedite our efforts to bring this potentially transformative therapy to patients. Given the need for new therapeutic options in this underserved population, we are committed to working closely with the FDA to accelerate its development." The ongoing Phase 1 multicenter study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CUSP06 in adults with platinum-refractory/resistant ovarian cancer and other advanced solid tumors (CUSP06-1001). Early data from the trial have shown promising anti-tumor activity and a manageable safety profile, supporting further development of the program. About CUSP06 CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a stable and homogenous ADC. The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased "bystander effect" compared to competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics in 2022. CUSP06 is being evaluated in a Phase 1 study in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. Additional information on the CUSP06-1001 (NCT06234423) trial can be found at clinicaltrials.gov. About Platinum-Resistant Ovarian Cancer Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States, with approximately 20,000 new cases diagnosed annually.[1] Platinum-based chemotherapy is a standard first-line treatment, but approximately 80% of patients who respond to initial treatment will develop platinum resistance, typically within two years.[2] Platinum-resistant ovarian cancer is defined as disease progression within six months of completing platinum-based therapy and carries a particularly poor prognosis, with median survival of only 9-12 months and limited effective treatment options.[2] Despite recent therapeutic advances, the 5-year survival rate for patients with platinum-resistant disease remains around 15%, highlighting a critical unmet need for new therapeutic approaches.[1],[3] About Fast Track Designation Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. Programs with FTD may benefit from more frequent meetings with the FDA, eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and the potential for a rolling review of the Biologics License Application (BLA). About OnCusp Therapeutics OnCusp Therapeutics, Inc., headquartered in Princeton, New Jersey, is a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients. OnCusp raised an oversubscribed $100 million Series A financing round in January 2024, co-led by Novo Holdings, OrbiMed, and F-Prime Capital. References [1]. American Cancer Society. "Cancer Facts & Figures 2023." Atlanta: American Cancer Society, 2023. [2]. Lheureux, Stephanie, Charlie Gourley, Ignace Vergote, and Amit M. Oza. "Epithelial Ovarian Cancer." The Lancet 393, no. 10177 (2019): 1240-1253. [3]. National Cancer Institute. "Surveillance, Epidemiology, and End Results (SEER) Program." Cancer Stat Facts: Ovarian Cancer. Accessed 2023. https://seer.cancer.gov/statfacts/html/ovary.html CONTACT: Becky Zhang, becky@chancebest.com
全球嵌入式系統研發領域之軟體領導者IAR今日宣布其嵌入式開發工具IAR Embedded Workbench Functional Safety於「EE Awards Asia 2024 亞洲金選獎」連續第三年榮獲產品獎類別 (Product Award Category)「開發工具獎 ( Development Kits)」。此榮耀歸功於IAR致力支持開發人員透過針對關鍵安全應用所提供通過認證之靜態分析工具C-STAT來創建安全、可靠且合規的嵌入式應用;更重要的是,IAR在地服務團隊皆為經認證之功能安全專家,可為客戶提供即時而全面性的專業服務。 IAR Embedded Workbench Functional Safety將靜態分析無縫整合至CI-based工作流程,使開發人員和團隊在自動化和遵循功能安全標準時更具信心。該工具通過TÜV SÜD認證,藉由執行全面性的靜態分析協助開發人員發揮符合安全標準的關鍵作用,並能偵測包括程式碼漏洞及偏離MISRA C與CERT C等程式碼撰寫標準的各種潛在問題。該保護性偵測機制的關鍵重要性在於協助防範在開發周期後期昂貴且耗時的修正作業,進而能強化整體可信賴性並加速產品上市。 「EE Awards Asia 2024 亞洲金選獎」主要表彰產業領域內的優秀企業、產品以及對產業貢獻卓著之人物,並且是亞洲及台灣電子產業中廣受讚譽之設計解決方案指南。2024年邀集全球170家企業、超過400份報名角逐獎項。其中,IAR Embedded Workbench Functional Safety從台灣及亞太區廣大網路用戶群、及主辦單位ASPENCORE旗下全球編輯群與業界專家之評選脫穎而出,使該公司的開發工具連續第三年榮獲「開發工具獎」。 IAR亞太區副總裁Kiyo Uemura表示:「IAR很榮幸在EE Awards Asia 2024連續第三次榮獲開發工具獎,連續獲獎證明IAR的開發工具獲得客戶和工程族群的廣泛認可和支持。隨著嵌入式系統複雜性不斷提升,功能安全變得越來越重要。透過選擇預先認證的解決方案,客戶將可節省寶貴的時間和成本,使其能更專注於程式碼和功能本身。IAR Embedded Workbench Functional Safety提供可支援標準和所涵蓋規則的寶貴資訊,進一步協助開發人員確保應用程式的合規性和可信賴性,輔以IAR專業的在地支援團隊,我們已準備好協助客戶成功實現下一個關鍵安全應用。」 更多關於已認證IAR Embedded Workbench Functional Safety資訊,及其他IAR 針對開發功能安全相關應用之解決方案請參閱: https://www.iar.com/products/requirements/functional-safety/.
VANCOUVER, BC, Nov. 21, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, Calif.-based genomic sequencer manufacturer, today announced at the 2024 Association for Molecular Pathology (AMP) Annual Meeting & Expo the launch of its mpox (MPXV) virus amplicon sequencing panel, part of its sequencing product portfolio for pathogenic microorganisms. Complete Genomics is at AMP this week at Booth #1524. The recent surge in mpox cases is attributed to a novel strain of the virus MPXV, which exists in two clades: clade I and clade II. The global outbreak in 2022 was driven by clade II, while the newly identified Ib clade of mpox has been spreading across Africa in recent months. According to STAT, 115,000 mpox cases – clade I and clade II - have been reported in 123 countries in 2024. This week, the Centers for Disease Control and Prevention confirmed that a strain of mpox previously undetected in the U.S. was confirmed by the California Dept. Of Public Health in an individual who had recently traveled from Eastern Africa. State health officials in California reported no evidence of transmission to other people in the case. "The new strain of the mpox virus demonstrates why it is crucial to public health for researchers worldwide, including American researchers, to access affordable and high-quality sequencing products," said Rob Tarbox, VP of Product and Marketing at Complete Genomics. "These products are rapidly upgraded to enhance the identification and monitoring of new mpox virus strains." The new mpox virus amplicon sequencing panel, a targeted sequencing product based on ATOPlex multiplex PCR technology and developed with proprietary reagents, instruments and software. It covers the full-length genome of the virus, enabling rapid identification and traceability, with relative quantification of the virus. The MPXV analysis software supports virus identification, mutation detection, and strain typing, allowing for rapid and accurate analysis of sequencing data. The panel is compatible with Complete Genomics sequencing instruments DNBSEQ-G99, DNBSEQ-E25, and DNBSEQ-G400 and features automated library preparation and data analysis. In South America, Complete Genomics has also launched an end-to-end NGS solution for DENV virus that causes dengue fever, including sample extraction ATOPlex amplicon-based library preparation, DNBSEQ sequencing, and data analysis. About Complete Genomics Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit www.completegenomics.com. * For Research Use Only. Not for use in diagnostic procedures.
全球嵌入式研發領域軟體與服務領導者IAR日前宣布,與鴻軒科技(SiliconAuto B. V.)合作。IAR將成為鴻軒科技之功能安全(FuSa)方案開發夥伴,透過IAR Embedded Workbench for Arm協助開發車用晶片,輔以C-STAT、C-RUN分析工具,以高整合度加速客戶產品上市,共同提升車用晶片安全功能,並推動未來汽車技術之發展。 鴻軒科技由鴻海科技集團與全球領導車廠Stellantis共同投資設立,專注設計適用於各類車用系統的晶片技術。鴻軒科技的三大產品線,包括微控制器(MCU)、SerDes 以及 SoC。這些技術推動了多樣ECU (electronic control unit),如BCM (body control module)、攝影機與顯示數據傳輸以及駕駛輔助系統等應用發展。 汽車產業中所運用之程式均須通過功能安全 (FuSa) 認證,並完成嚴格的檢查程序與測試階段,使用合適的工具是確保程式碼品質、加速開發進度及提升效率的關鍵因素。鴻軒科技在選擇車用晶片開發夥伴時,始終將功能安全視為核心需求,因此選擇 IAR 作為其功能安全 (FuSa) 解決方案的合作夥伴,共同推動高效能且高可靠性的開發流程。 鴻軒科技系統平台設計處處長林宏文表示:「我們的客戶群對於合作方的解決方案品質具有非常嚴格的要求,因此在專案最初期透過其推薦、已驗證的IAR方案讓我們深具信心。IAR 於FuSa的深厚經驗讓我們可快速地進行開發與驗證,維持開發版本一致性。更重要的是,IAR在地服務團隊為擁有認證之功能安全專家,能提供最即時與完備的專業服務,這對於高度需要技術支援之車用產業特別重要。」 鴻軒科技選用IAR Embedded Workbench for Arm進行驅動程式開發及驗證於IC的正常運行,相關合作也使鴻軒的MCU能充分發揮於BCM車身控制器的高度安全功能。IAR Embedded Workbench for Arm完備的開發工具鏈包含高度最佳化的編譯器以及先進除錯功能,如IAR提供的程式碼分析工具主動找出各種程式碼問題、並提升程式碼品質、及盡可能減少潛在的資安攻擊途徑,確保發掘與消弭各種防禦漏洞。 IAR 亞太區副總裁Kiyo Uemura表示:「IAR很高興能提供最佳的功能安全解決方案,協助鴻軒提供更可靠的車用晶片技術。全球的汽車產業蘊含極大的潛力,MCU的發展已成為汽車電子智慧創新的關鍵推動因素,IAR 將繼續不斷地與如鴻軒科技等優質生態夥伴合作,為安全嵌入式應用奠定基礎,提供從產品開發到大量生產的安全防護,並支援全球汽車產業創造今日的產品和實現未來的創新。」 IAR提供從設計到開發之整個流程具備完全整合且一致性的解決方案,協助簡化設計流程,節省設計時間與成本,使客戶專注於創新。IAR Embedded Workbench for Arm 不僅具高度整合性,同時也具備編碼一致性,不僅可使客戶的開發、驗證更有效率,更可協助客戶更快將產品上市,使其先掌握並滿足車用市場未來需求。 更多關於IAR Embedded Workbench for Arm之資訊請瀏覽www.iar.com/ewarm
FSG (功能安全專家小組)的創始成員SGS Taiwan、晶心科技(Andes Technology)及IAR今日於新竹舉辦技術研討會,邀集產業夥伴及領域專家針對RISC-V環境之功能安全應用,以及如何因應ISO 26262標準縮短認證流程、加速設計進行交流,研討會吸引廣泛參與,充分展現業界對於深入了解RISC-V開發環境的高度需求。 隨著RISC-V核心在SoC和商用微控制器的採用漸趨普遍,對於將在近期設計中選用RISC-V的企業而言,對於功能安全的要求也越來越高,如何整合高品質的軟硬體工具和開發解決方案以因應廣泛的測試和驗證,已成為取得RISC-V功能安全認證以加速產品開發的重要關鍵。 本次技術研討會針對在RISC-V背景下,如何採用更新功能安全標準和認證工作流程進行探討,同時說明如何選擇認證的合規軟體開發工具以因應測試挑戰,透過可擴展的軟體架構因應各種應用需求。會中,晶心科技分享了RISC-V方案產品、入門方式及客戶成功案例,SGS則針對ISO 26262的發展歷程及導入進行說明,而IAR則介紹支援RISC-V架構的預認證C-STAT靜態分析工具如何加速程式碼品質自動化,透過軟體品質和安全性的提升確保合規性,節省開發時間。 IAR亞太區副總裁Kiyo Uemura表示:「IAR致力於賦能開發者和推動整個嵌入式RISC-V產業發展。因應各界對於RISC-V 技術的持續採用,IAR很高興能與FSG成員攜手提升RISC-V產品功能安全,也承諾將透過專業的開發工具支持RISC-V生態系統和客戶,協助開發高品質嵌入式應用,推升RISC-V的持續發展。」 晶心科技資深技術經理王庭昭表示:「很高興與FSG成員合作,讓客戶在其產品認證過程中充分利用經認證的安全解決方案。晶心科技是第一家獲得 ISO 26262全面合規的RISC-V CPU IP公司,隨著通過認證之開發流程到位,我們已備妥完整的ISO 26262 功能安全系列產品路線圖以利產業供應鏈的發展。」 SGS技術經理暨功能安全專家張國樑表示:「我們很高興能與FSG小組成員及晶心科技透過此次技術研討會延伸功能安全標準應用與技術,同時分享最新的ISO 26262標準發展進程。SGS將持續提供協助RISC-V產品軟硬體設計與驗證,與FSG成員共同探索市場商機。」 FSG繼2024年4月成立後獲得業界廣泛支持,近日觸角更延伸至東南亞,透過舉辦嵌入式開發環境功能安全研討會為當地產業提供最新技術及服務諮詢。歡迎瀏覽FSG.tw網站,掌握最新功能安全技術發展及下載趨勢白皮書。也歡迎提出設計應用諮詢,由功能安全專家小組為您提供專業解方。 關於FSG FSG(功能安全專家小組)成立於2024年4月,由一群致力於提供一站式功能安全技術諮詢服務、並為提高嵌入式產業安全性之企業夥伴組成。FSG致力於提供與功能安全認證相關的技術、產品和開發資源,協助產業提升功能安全認證價值。
A12 藝術空間
C-STAT
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)